Advancing
Medicine with
PrecisionTM
Nasdaq: PGEN
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.
NASDAQ GS: PGEN
$3.50
+0.56 (0.00%)
Data as of Apr 20, 2020 4:00 PM EDT
Copyright West LLC. Minimum 15 minutes delayed.
View All
Press Releases
Feb 24, 2020
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Feb 24, 2020
Study for First-in-Class PRGN-2009 Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Feb 24, 2020
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors